Do analysts rate TNFA or BRNS?

Barinthus Biotherapeutics has a consensus price target of $4.00, indicating a potential upside of 564.45%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than TNF Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TNFA or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat TNF Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets TNF Pharmaceuticals N/A -69.21% -33.98% Barinthus Biotherapeutics N/A -63.83% -48.77%

Do analysts prefer EVAX or TNFA?

Evaxion A/S presently has a consensus price target of $11.00, suggesting a potential upside of 275.43%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than TNF Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EVAX or TNFA more profitable?

TNF Pharmaceuticals' return on equity of -69.21% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% TNF Pharmaceuticals N/A -69.21% -33.98%

Do analysts prefer TXMD or TNFA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TNFA or AYTU?

Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 397.69%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Aytu BioPharma is more favorable than TNF Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aytu BioPharma 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend SKYE or TNFA?

Skye Bioscience presently has a consensus price target of $8.50, indicating a potential upside of 1,203.88%. Given Skye Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Skye Bioscience is more favorable than TNF Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, SKYE or TNFA?

Skye Bioscience is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.44 N/A TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A

Is SKYE or TNFA more profitable?

TNF Pharmaceuticals' return on equity of -69.21% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% TNF Pharmaceuticals N/A -69.21% -33.98%

TNF Pharmaceuticals (TNFA) Competitors

$3.23 -0.12 (-3.58%)

As of 07/24/2026

Compare

TNFA vs. BRNS, EVAX, TXMD, AYTU, and SKYE

Should you buy TNF Pharmaceuticals stock or one of its competitors? MarketBeat compares TNF Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TNF Pharmaceuticals include Barinthus Biotherapeutics (BRNS), Evaxion A/S (EVAX), TherapeuticsMD (TXMD), Aytu BioPharma (AYTU), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry.

How does TNF Pharmaceuticals compare to Barinthus Biotherapeutics?

TNF Pharmaceuticals (NASDAQ:TNFA) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

TNF Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.41, indicating that its share price is 141% less volatile than the broader market.

In the previous week, Barinthus Biotherapeutics had 2 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 2 mentions for Barinthus Biotherapeutics and 0 mentions for TNF Pharmaceuticals. Barinthus Biotherapeutics' average media sentiment score of 1.44 beat TNF Pharmaceuticals' score of 0.00 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
TNF Pharmaceuticals	Neutral
Barinthus Biotherapeutics	Positive

9.6% of TNF Pharmaceuticals shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 0.5% of TNF Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Barinthus Biotherapeutics has a consensus price target of $4.00, indicating a potential upside of 564.45%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than TNF Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TNF Pharmaceuticals has higher earnings, but lower revenue than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A
Barinthus Biotherapeutics	$14.97M	1.64	-$66.43M	-$1.29	N/A

Barinthus Biotherapeutics' return on equity of -63.83% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-69.21%	-33.98%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Summary

Barinthus Biotherapeutics beats TNF Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

In the previous week, Evaxion A/S had 1 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 1 mentions for Evaxion A/S and 0 mentions for TNF Pharmaceuticals. Evaxion A/S's average media sentiment score of 1.89 beat TNF Pharmaceuticals' score of 0.00 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion A/S	Very Positive
TNF Pharmaceuticals	Neutral

Evaxion A/S has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Evaxion A/S has higher revenue and earnings than TNF Pharmaceuticals. Evaxion A/S is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.25	-$7.71M	-$1.47	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

TNF Pharmaceuticals' return on equity of -69.21% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Evaxion A/S presently has a consensus price target of $11.00, suggesting a potential upside of 275.43%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than TNF Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Evaxion A/S beats TNF Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, TherapeuticsMD had 1 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 1 mentions for TherapeuticsMD and 0 mentions for TNF Pharmaceuticals. TherapeuticsMD's average media sentiment score of 1.87 beat TNF Pharmaceuticals' score of 0.00 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
TNF Pharmaceuticals	Neutral

TherapeuticsMD has higher revenue and earnings than TNF Pharmaceuticals. TNF Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.89	-$570K	$0.06	34.33
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

TherapeuticsMD has a net margin of 5.34% compared to TNF Pharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Summary

TherapeuticsMD beats TNF Pharmaceuticals on 11 of the 12 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Aytu BioPharma?

TNF Pharmaceuticals (NASDAQ:TNFA) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

TNF Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. TNF Pharmaceuticals' return on equity of -69.21% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-69.21%	-33.98%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Aytu BioPharma has higher revenue and earnings than TNF Pharmaceuticals. Aytu BioPharma is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A

In the previous week, Aytu BioPharma had 1 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 1 mentions for Aytu BioPharma and 0 mentions for TNF Pharmaceuticals. Aytu BioPharma's average media sentiment score of 0.44 beat TNF Pharmaceuticals' score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
TNF Pharmaceuticals	Neutral
Aytu BioPharma	Neutral

TNF Pharmaceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 397.69%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Aytu BioPharma is more favorable than TNF Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aytu BioPharma beats TNF Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Skye Bioscience has a beta of 2.94, meaning that its share price is 194% more volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

Skye Bioscience presently has a consensus price target of $8.50, indicating a potential upside of 1,203.88%. Given Skye Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Skye Bioscience is more favorable than TNF Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TNF Pharmaceuticals' return on equity of -69.21% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Skye Bioscience is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

In the previous week, Skye Bioscience had 1 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 1 mentions for Skye Bioscience and 0 mentions for TNF Pharmaceuticals. Skye Bioscience's average media sentiment score of 1.87 beat TNF Pharmaceuticals' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Skye Bioscience	Very Positive
TNF Pharmaceuticals	Neutral

Summary

Skye Bioscience beats TNF Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get TNF Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNFA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNFA vs. The Competition

Export

Metric	TNF Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.97M	$3.08B	$6.93B	$12.20B
Dividend Yield	N/A	2.07%	2.67%	9.41%
P/E Ratio	-0.01	12.52	22.28	21.32
Price / Sales	N/A	339.70	523.79	89.73
Price / Cash	N/A	27.32	49.81	58.78
Price / Book	0.01	4.13	10.28	6.01
Net Income	-$23.36M	$65.94M	$3.60B	$331.99M
7 Day Performance	-6.10%	-4.16%	-1.27%	-0.63%
1 Month Performance	-15.22%	-3.76%	-0.37%	-2.00%
1 Year Performance	-72.35%	9.94%	18.30%	13.62%

TNF Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNFA TNF Pharmaceuticals	N/A	$3.23 -3.6%	N/A	-74.6%	$5.97M	N/A	N/A	6
BRNS Barinthus Biotherapeutics	3.1461 of 5 stars	$0.61 -1.8%	$4.00 +560.0%	-65.5%	$25.20M	$14.97M	N/A	107	Positive News Analyst Upgrade Short Interest Decrease Gap Up
EVAX Evaxion A/S	3.2483 of 5 stars	$3.02 +2.7%	$11.00 +264.2%	+8.1%	$24.52M	$7.53M	N/A	60	Positive News
TXMD TherapeuticsMD	1.7263 of 5 stars	$2.04 -3.3%	N/A	+80.7%	$24.42M	$3.02M	34.00	420
AYTU Aytu BioPharma	2.0461 of 5 stars	$2.18 +0.9%	$10.75 +393.1%	-18.5%	$23.18M	$66.38M	N/A	160	Negative News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNFA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TNF Pharmaceuticals (TNFA) Competitors

TNFA vs. BRNS, EVAX, TXMD, AYTU, and SKYE

How does TNF Pharmaceuticals compare to Barinthus Biotherapeutics?

Summary

How does TNF Pharmaceuticals compare to Evaxion A/S?

Summary

How does TNF Pharmaceuticals compare to TherapeuticsMD?

Summary

How does TNF Pharmaceuticals compare to Aytu BioPharma?

Summary

How does TNF Pharmaceuticals compare to Skye Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA vs. The Competition

TNF Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TNF Pharmaceuticals (TNFA) Competitors

TNFA vs. BRNS, EVAX, TXMD, AYTU, and SKYE

How does TNF Pharmaceuticals compare to Barinthus Biotherapeutics?

Which has more risk & volatility, TNFA or BRNS?

Does the media favor TNFA or BRNS?

Do insiders & institutionals believe in TNFA or BRNS?

Do analysts rate TNFA or BRNS?

Which has stronger valuation & earnings, TNFA or BRNS?

Is TNFA or BRNS more profitable?

Summary

How does TNF Pharmaceuticals compare to Evaxion A/S?

Does the media refer more to EVAX or TNFA?

Which has more volatility and risk, EVAX or TNFA?

Do institutionals and insiders hold more shares of EVAX or TNFA?

Which has better valuation & earnings, EVAX or TNFA?

Is EVAX or TNFA more profitable?

Do analysts prefer EVAX or TNFA?

Summary

How does TNF Pharmaceuticals compare to TherapeuticsMD?

Do insiders & institutionals hold more shares of TXMD or TNFA?

Does the media prefer TXMD or TNFA?

Which has preferable valuation and earnings, TXMD or TNFA?

Do analysts prefer TXMD or TNFA?

Which has more volatility & risk, TXMD or TNFA?

Is TXMD or TNFA more profitable?

Summary

How does TNF Pharmaceuticals compare to Aytu BioPharma?

Do insiders & institutionals have more ownership in TNFA or AYTU?

Is TNFA or AYTU more profitable?

Which has better valuation and earnings, TNFA or AYTU?

Does the media favor TNFA or AYTU?

Which has more risk and volatility, TNFA or AYTU?

Do analysts prefer TNFA or AYTU?

Summary

How does TNF Pharmaceuticals compare to Skye Bioscience?

Do insiders & institutionals believe in SKYE or TNFA?

Which has more volatility and risk, SKYE or TNFA?

Do analysts recommend SKYE or TNFA?

Is SKYE or TNFA more profitable?

Which has better earnings and valuation, SKYE or TNFA?

Does the media prefer SKYE or TNFA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA vs. The Competition

TNF Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools